The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Overcoming resistance to ICIs in biliary tract cancers
Rachna T. Shroff, MD, MS, University of Arizona College of Medicine, Tucson, AZ, shares strategies to enhance the efficacy of immune checkpoint inhibitors (ICIs) in patients with biliary tract cancers. Results from the TOPAZ-1 trial (NCT03875235) of durvalumab with gemcitabine and cisplatin have shown the efficacy of ICIs with chemotherapy. Additional trials such as the KEYNOTE-966 trial (NCT04003636) of pembrolizumab and others investigating atezolizumab and bevacizumab will also provide insight into the efficacy of this therapeutic modality. Alternative strategies include dual targeting of CTLA-4, PD-L1, or LAG-3. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
